C4 Therapeutics Inc
CCCC
Get informed when a big investor buys or sells
+ FollowMarket Cap$343.73M
Close$
$-3.15
174.6% downside
Current Fair Value
174.6% downsideOvervalued by 174.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $343.73 Million |
|---|---|
| Enterprise Value | $351.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.27 |
| Beta | 2.93 |
| Outstanding Shares | 126,074,555 |
Return
| Return on Equity | -44.31% |
|---|---|
| Return on Assets | -31.56% |
| Return on Invested Capital | -36.82% |
Valuation & Multiples
| P/E Ratio | -3.49 |
|---|---|
| PEG | 76.94 |
| Price to Sales | -4.22 |
| Price to Book Ratio | 4.22 |
| Enterprise Value to Revenue | -18.69 |
| Enterprise Value to EBIT | -3.16 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$4.80 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$8.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1956▼ 52.71% |
|---|---|
| Total Calls | 238,800▲ 126.78% |
| Total Puts | 46,700▼ 38.63% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.93%▼ 8.09% |
|---|---|
| Total Invested | $221.30M▲ 45.14% |
| Investors Holding | 128▲ 20.00% |
ESG Score
No data
About C4 Therapeutics Inc
99 employeesC4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and o...